Characterization of antiplatelet response to low-dose cangrelor utilizing platelet function testing in neuroendovascular patients.

Devin N HoldenPouya EntezamiMaximilian C BushNicholas C FieldAlexandra R PaulAlan S BoulosJunichi YamamotoJohn C Dalfino

Published in: Pharmacotherapy (2021)

Utilizing low doses of cangrelor with platelet function testing is an option during emergent neuroendovascular stenting and bridging. Cangrelor demonstrates significant variability in response at low doses and exhibits a dose response relationship when PFT is utilized.

Keyphrases

low dose
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
prognostic factors
patient reported outcomes